MetaCap

Precision BioSciences (DTIL) vs X4 Pharmaceuticals (XFOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precision BioSciences (DTIL) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 48.0% versus a loss of 20.0%. Over five years, DTIL leads with a -97.2% price change compared with -97.8% for XFOR. X4 Pharmaceuticals is the larger company by market cap ($306.3 million vs $282.5 million), about 1.1 times the size.

On valuation, X4 Pharmaceuticals trades at a lower trailing P/E (5.5x vs 29.6x for Precision BioSciences). Precision BioSciences converts more of its revenue into profit, with a net margin of -133.4% versus -1218.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DTIL+48.00%XFOR-20.00%
+119%+39%-42%
Nov 21, 20251 yearNov 20, 2026
DTIL-97.36%XFOR-97.91%
+5%-50%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DTIL versus XFOR key metrics
MetricDTILXFOR
Share price$7.40$3.00
Market cap$282.46M$306.34M
1-day change+7.09%+1.35%
YTD return+77.88%-25.00%
1-year return+48.00%-20.00%
5-year return-97.23%-97.79%
P/E ratio (TTM)29.605.45
EPS (TTM)$0.25$0.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$34.26M$6.50M
Revenue growth (YoY)-50.12%+150.00%
Net income (latest FY)$-45.72M$-79.20M
Gross margin—11.43%
Operating margin-152.19%-1336.66%
Net margin-133.45%-1218.45%
52-week high$11.29$4.83
52-week low$3.53$2.43
Distance from 52-week high-34.46%-37.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+297.30%+286.67%
Average volume319.79K877.70K
Shares outstanding38.17M102.11M
Employees6945
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DTIL has outperformed XFOR by 68.0 percentage points over the past year.
  • Precision BioSciences trades at a higher earnings multiple (29.6x vs 5.5x trailing P/E).
  • Precision BioSciences is more profitable, keeping -133.4 cents of every revenue dollar as net income versus -1218.4 cents for X4 Pharmaceuticals.
  • X4 Pharmaceuticals grew revenue faster in its latest fiscal year (+150.00% vs -50.12%).

About Precision BioSciences

DTIL stock →

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees

About X4 Pharmaceuticals

XFOR stock →

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees

DTIL vs XFOR FAQ

Which is bigger, Precision BioSciences or X4 Pharmaceuticals?

X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $306.34M compared with $282.46M for Precision BioSciences (DTIL).

Which stock has performed better over the past year, DTIL or XFOR?

DTIL returned +48.00% over the past 12 months, compared with -20.00% for XFOR (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, DTIL or XFOR?

XFOR has the lower trailing P/E at 5.5, versus 29.6 for DTIL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Precision BioSciences and X4 Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons